Cargando…

Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy

Patients with severely impaired antibody responses represent a group at-risk in the SARS-CoV-2 pandemic due to the lack of Spike-specific neutralizing antibodies. The main objective of this paper was to assess, by a longitudinal prospective study, COVID-19 infection and mortality rates, and disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Milito, Cinzia, Cinetto, Francesco, Palladino, Andrea, Garzi, Giulia, Punziano, Alessandra, Lagnese, Gianluca, Scarpa, Riccardo, Rattazzi, Marcello, Pesce, Anna Maria, Pulvirenti, Federica, Di Napoli, Giulia, Spadaro, Giuseppe, Carsetti, Rita, Quinti, Isabella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138935/
https://www.ncbi.nlm.nih.gov/pubmed/35625763
http://dx.doi.org/10.3390/biomedicines10051026
_version_ 1784714741571125248
author Milito, Cinzia
Cinetto, Francesco
Palladino, Andrea
Garzi, Giulia
Punziano, Alessandra
Lagnese, Gianluca
Scarpa, Riccardo
Rattazzi, Marcello
Pesce, Anna Maria
Pulvirenti, Federica
Di Napoli, Giulia
Spadaro, Giuseppe
Carsetti, Rita
Quinti, Isabella
author_facet Milito, Cinzia
Cinetto, Francesco
Palladino, Andrea
Garzi, Giulia
Punziano, Alessandra
Lagnese, Gianluca
Scarpa, Riccardo
Rattazzi, Marcello
Pesce, Anna Maria
Pulvirenti, Federica
Di Napoli, Giulia
Spadaro, Giuseppe
Carsetti, Rita
Quinti, Isabella
author_sort Milito, Cinzia
collection PubMed
description Patients with severely impaired antibody responses represent a group at-risk in the SARS-CoV-2 pandemic due to the lack of Spike-specific neutralizing antibodies. The main objective of this paper was to assess, by a longitudinal prospective study, COVID-19 infection and mortality rates, and disease severity in the first two years of the pandemic in a cohort of 471 Primary Antibody Defects adult patients. As secondary endpoints, we compared SARS-CoV-2 annual mortality rate to that observed over a 10-year follow-up in the same cohort, and we assessed the impact of interventions done in the second year, vaccination and anti-SARS-CoV-2 monoclonal antibodies administration on the disease outcome. Forty-one and 84 patients were infected during the first and the second year, respectively. Despite a higher infection and reinfection rate, and a higher COVID-19-related mortality rate compared to the Italian population, the pandemic did not modify the annual mortality rate for any cause in our cohort compared to that registered over the last ten years in the same cohort. PADs patients who died from COVID-19 had an underlying end-stage lung disease. We showed a beneficial effect of MoAbs administration on the likelihood of hospitalization and development of severe disease. In conclusion, COVID-19 did not cause excess mortality in Severe Antibody Deficiencies.
format Online
Article
Text
id pubmed-9138935
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91389352022-05-28 Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy Milito, Cinzia Cinetto, Francesco Palladino, Andrea Garzi, Giulia Punziano, Alessandra Lagnese, Gianluca Scarpa, Riccardo Rattazzi, Marcello Pesce, Anna Maria Pulvirenti, Federica Di Napoli, Giulia Spadaro, Giuseppe Carsetti, Rita Quinti, Isabella Biomedicines Article Patients with severely impaired antibody responses represent a group at-risk in the SARS-CoV-2 pandemic due to the lack of Spike-specific neutralizing antibodies. The main objective of this paper was to assess, by a longitudinal prospective study, COVID-19 infection and mortality rates, and disease severity in the first two years of the pandemic in a cohort of 471 Primary Antibody Defects adult patients. As secondary endpoints, we compared SARS-CoV-2 annual mortality rate to that observed over a 10-year follow-up in the same cohort, and we assessed the impact of interventions done in the second year, vaccination and anti-SARS-CoV-2 monoclonal antibodies administration on the disease outcome. Forty-one and 84 patients were infected during the first and the second year, respectively. Despite a higher infection and reinfection rate, and a higher COVID-19-related mortality rate compared to the Italian population, the pandemic did not modify the annual mortality rate for any cause in our cohort compared to that registered over the last ten years in the same cohort. PADs patients who died from COVID-19 had an underlying end-stage lung disease. We showed a beneficial effect of MoAbs administration on the likelihood of hospitalization and development of severe disease. In conclusion, COVID-19 did not cause excess mortality in Severe Antibody Deficiencies. MDPI 2022-04-29 /pmc/articles/PMC9138935/ /pubmed/35625763 http://dx.doi.org/10.3390/biomedicines10051026 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Milito, Cinzia
Cinetto, Francesco
Palladino, Andrea
Garzi, Giulia
Punziano, Alessandra
Lagnese, Gianluca
Scarpa, Riccardo
Rattazzi, Marcello
Pesce, Anna Maria
Pulvirenti, Federica
Di Napoli, Giulia
Spadaro, Giuseppe
Carsetti, Rita
Quinti, Isabella
Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy
title Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy
title_full Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy
title_fullStr Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy
title_full_unstemmed Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy
title_short Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy
title_sort mortality in severe antibody deficiencies patients during the first two years of the covid-19 pandemic: vaccination and monoclonal antibodies efficacy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138935/
https://www.ncbi.nlm.nih.gov/pubmed/35625763
http://dx.doi.org/10.3390/biomedicines10051026
work_keys_str_mv AT militocinzia mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy
AT cinettofrancesco mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy
AT palladinoandrea mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy
AT garzigiulia mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy
AT punzianoalessandra mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy
AT lagnesegianluca mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy
AT scarpariccardo mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy
AT rattazzimarcello mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy
AT pesceannamaria mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy
AT pulvirentifederica mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy
AT dinapoligiulia mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy
AT spadarogiuseppe mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy
AT carsettirita mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy
AT quintiisabella mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy